76 results
8-K
EX-10.1
v034s
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
nderuz
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
EX-1.1
zwaj8suju8wp
14 Feb 24
Other Events
4:11pm
8-K
EX-99.1
0054ihxj
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.2
lnn cbf7xoh559
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-2.1
vk3ta eg3qog097a
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
EX-99.1
nv78sh7 co3a
11 Jan 24
Regulation FD Disclosure
5:27pm
8-K
EX-10.1
zpnpu0r
29 Dec 23
Departure of Directors or Certain Officers
5:00pm
8-K
EX-99.1
cfl90 tfk8
15 Nov 23
Regulation FD Disclosure
6:03am
424B3
fsrg6
28 Aug 23
Prospectus supplement
9:10am
S-4/A
92og gihwvinl
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
S-4
h0wa4mtesn25m2ap516c
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
S-4
EX-10.43
1sqmeesg4jys2k0
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm